Clinical trial · Interventional
RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
A Prospective Multicenter Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of the RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
NCT04091672CI-TRIAL-00079233completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective randomized within-subject controlled study to compare the clinical performance of conventional autografting with and without the RECELL system on acute non-burn full-thickness skin defects.
Conditions
Conditions (10)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cellulitis | — | UNRESOLVED | — |
| Crush Injuries | — | UNRESOLVED | — |
| Degloving Injuries | — | UNRESOLVED | — |
| Full-thickness Skin Defects | — | UNRESOLVED | — |
| Gun Shot Wound | — | UNRESOLVED | — |
| Infection | — | UNRESOLVED | — |
| Laceration of Skin | — | UNRESOLVED | — |
| Necrotizing Fasciitis | — | UNRESOLVED | — |
| Skin Cancer | Malignant Skin Neoplasm | ALIAS | 0.90 |
| Surgical Wound | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Control Intervention (Conventional Autograft) | Procedure | — | UNRESOLVED |
| Investigational Intervention (RECELL + more widely meshed autograft) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- All Participants (within patient control)
- description
- Each participant will serve as their own Control, receiving both Control and Investigational Interventions randomly allocated to treatment of a portion of a full-thickness skin defect.
- interventionNames
- Procedure: Control Intervention (Conventional Autograft)
- Device: Investigational Intervention (RECELL + more widely meshed autograft)
Primary outcomes (2)
- measure
- Incidence of Treatment Area Healing
- timeFrame
- Prior to or at 8 weeks
- description
- The incidence of healing is hypothesized to be non-inferior for RECELL-treated areas (Investigational Intervention) as compared to Control areas (Control Intervention). Healing is defined as complete wound closure characterized by 100% skin re-epithelialization without drainage, confirmed at two consecutive study visits at least 2 weeks apart by direct visualization by a Blinded Evaluator.
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 5 Years
Show eligibility criteria text
Inclusion Criteria: 1. The patient requires autografting for treatment of an acute full-thickness skin defect (e.g., trauma- or surgery-related). 2. The maximum area requiring autografting is 50% Total Body Surface Area (TBSA). 3. Two comparable areas requiring autografting, each at least 160 cm2 (or 320 cm2 contiguous), excluding face and genitalia. When hands or joints are included in the treatment areas, comparability of treatment areas means that each area (RECELL and Control) must include the same contralateral joint and/or hand. 4. The patient is at least 5 years of age. 5. The patient (or parent/guardian) is willing and able to comply with all compulsory study procedures and visit schedule. 6. The patient agrees to abstain from any other treatment (e.g., external fixation) of the study treatment areas for the duration of his/her participation the study (1 year). 7. The patient agrees to abstain from enrollment in any other interventional clinical trial for the duration of his/her participation the study (1 year). 8. In the opinion of the investigator, the patient and/or guardian must be able to: 1. Understand the full nature and purpose of the study, including possible risks and adverse events, 2. Understand instructions, and 3. Provide voluntary informed written consent. Exclusion Criteria: 1. Not able to understand English or Spanish. 2. The area requiring autografting sustained a burn injury. 3. The treatment area has previously failed to heal subsequent to surgical intervention for closure. 4. The patient is unable to follow the protocol requirements. 5. The patient has a condition that in the investigator's opinion may compromise patient safety or trial objectives. 6. Current use of medications that in the investigator's opinion may compromise patient safety or trial objectives. 7. The patient has a known hypersensitivity to trypsin or compound sodium lactate for irrigation (Hartmann's) solution. 8. The patient is pregnant or breast-feeding (pregnancy test should be performed in accordance with local institutional requirements). 9. Life expectancy is less than 1 year.
References
Publications (1)
- DERIVEDHenry S, Mapula S, Grevious M, Foster KN, Phelan H, Shupp J, Chan R, Harrington D, Mashruwala N, Brown DA, Mir H, Singer G, Cordova A, Rae L, Chin T, Castanon L, Bell D, Hughes W, Molnar JA. Maximizing wound coverage in full-thickness skin defects: A randomized-controlled trial of autologous skin cell suspension and widely meshed autograft versus standard autografting. J Trauma Acute Care Surg. 2024 Jan 1;96(1):85-93. doi: 10.1097/TA.0000000000004120. Epub 2023 Sep 1. PMID 38098145